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Introduction {#jdi12919-sec-0001}
============

Acute graft‐versus‐host disease (aGvHD) represents a frequent and potentially life‐threatening complication occurring after allogeneic hematopoietic stem cell transplantation, and is characterized by an activation of donor T cells and release of pro‐inflammatory mediators leading to host tissue apoptosis and necrosis affecting the skin, gastrointestinal tract, and liver[1](#jdi12919-bib-0001){ref-type="ref"}.

As first‐line standard therapy, high‐dose systemic glucocorticoids are recommended[2](#jdi12919-bib-0002){ref-type="ref"}, causing steroid‐induced hyperglycemia (SIHG) in up to 80% of treated patients[3](#jdi12919-bib-0003){ref-type="ref"}, [4](#jdi12919-bib-0004){ref-type="ref"}.

We and others have recently identified SIHG as a potent and independent predictor for adverse outcome in patients with hematological malignancy[5](#jdi12919-bib-0005){ref-type="ref"} and aGvHD[4](#jdi12919-bib-0004){ref-type="ref"}, [6](#jdi12919-bib-0006){ref-type="ref"}. Whether hyperglycemia represents a causal contributor to inferior outcome and an intensive glucose‐lowering strategy might have an impact on the unfavorable prognosis remains unclear to date and needs to be further investigated in a randomized controlled trial.

During the past decades, automated decision support systems (DSS) recommending insulin dosing for hospitalized patients have been repeatedly tested and introduced into clinical practice[7](#jdi12919-bib-0007){ref-type="ref"}, [8](#jdi12919-bib-0008){ref-type="ref"}. Until present, such systems were exclusively tested and approved for the treatment of in‐hospital (stress) hyperglycemia or type 2 diabetes mellitus, but not for patients with SIHG.

The aim of the present study was to evaluate the feasibility and safety using an automated DSS that incorporates an algorithm for basal--bolus insulin therapy (GlucoTab) in hospitalized patients with aGvHD in a randomized controlled pilot trial as a prerequisite for a future multicenter outcome trial comparing intensive glucose control achieved by a DSS with conventional glucose control.

Methods {#jdi12919-sec-0002}
=======

Study design {#jdi12919-sec-0003}
------------

We carried out a single center, randomized, controlled feasibility trial in 10 hospitalized aGvHD patients developing hyperglycemia (i.e., \>2 fasting glucose values \>140 mg/dL) after initiation of systemic glucocorticoid therapy.

The study was approved by the local ethics committee (27‐116 ex 14/15), registered (EudraCT Number: 2014‐004418‐27) and carried out in accordance with the declaration of Helsinki. All patients gave written consent before any study‐related procedure.

Participants were randomly assigned using a web‐based randomization tool ([www.randomizer.at](http://www.randomizer.at)) to either insulin therapy suggested by GlucoTab (GT group) or to routine care according to local standards of care (SOC group)[9](#jdi12919-bib-0009){ref-type="ref"}. Follow‐up duration was 6 months. If patients were readmitted to hospital during the follow‐up period, they were treated according to the initial randomization result.

Despite the feasibility design and therefore small patient population, a randomized controlled trial design was chosen in order to oppose two different therapeutic approaches for the management of in‐hospital hyperglycemia in patients with aGvHD. The primary aim of the study was to investigate the feasibility and safety of GlucoTab in the treatment of SIHG. Feasibility was assessed by the median glucose and percentage of plasma glucose (PG) values in the target range during systemic corticosteroid therapy. The main safety end‐point was the number of hypoglycemic events.

GlucoTab^®^ {#jdi12919-sec-0004}
-----------

GlucoTab (Decide, clinical software GmbH, Graz, Austria) is a DSS integrated in a mobile, handheld tablet computer suggesting subcutaneous basal--bolus insulin therapy provided by the incorporated standardized insulin dosing algorithm. This device has previously been tested and implemented in routine care (CE certified in 2013) in hospitalized non‐critically ill patients with hyperglycemia with or without diabetes mellitus, and has been shown to be an effective tool for the establishment of safe and tight glycemic control. However, GlucoTab has not been used for the management of SIHG thus far[7](#jdi12919-bib-0007){ref-type="ref"}, [10](#jdi12919-bib-0010){ref-type="ref"}. GlucoTab therapy requires four capillary glucose measurements per day (pre‐meal, bedtime), and provides both bolus and basal insulin dosing suggestions. Once a patient is registered to be treated with the DSS, it recommends a first total daily insulin dose based on age, renal function and body mass index. During the course of treatment, the incorporated algorithm adapts its insulin suggestions to retrospective glycemic trends. The current version of the algorithm proposes basal and bolus insulin in a proportion of 50:50%, with the largest bolus of short‐acting insulin in the morning. Dose suggestions can be overruled at any time by medical staff if deemed necessary or reasonable. In the present study, insulins aspart (NovoNordisk, Bagsvaerd, Denmark) and glargine (Sanofi‐Aventis, Frankfurt am Main, Germany) were used. Further information characterizing the functionality of the algorithm and its efficacy and usability shown in previous studies are described elsewhere in detail[7](#jdi12919-bib-0007){ref-type="ref"}, [10](#jdi12919-bib-0010){ref-type="ref"}.

For SOC, antihyperglycemic therapy was carried out at the discretion of the treating physician. According to the protocol, four daily glucose measurements were also requested in the SOC group throughout the trial.

Statistical analysis {#jdi12919-sec-0005}
--------------------

For collection of baseline and aGvHD characteristics, we used descriptive statistics. Continuous data following a normal distribution are given as means with standard deviation, and variables with a skewed distribution are presented as medians with interquartile range (IQR). Categorical data are presented as percentages. Comparative analysis and significance testing were carried out using the Mann--Whitney *U*‐test and χ^2^‐test. Statistical analyses were carried out with SPSS version 22.0 (IBM Corporation, Armonk, NY, USA). As the present study was a feasibility trial, no formal sample size calculation was carried out.

Results {#jdi12919-sec-0006}
=======

Patient characteristics {#jdi12919-sec-0007}
-----------------------

We included 10 patients (7 women) with aGvHD in the present randomized controlled feasibility trial. The mean age was 55 ± 13 versus 60 ± 4 years for GT and SOC, respectively. Table [1](#jdi12919-tbl-0001){ref-type="table"} shows further patient characteristics.

###### 

Patient characteristics

                                 GT (*n* = 5)         SOC (*n* = 5)          *P*‐value
  ------------------------------ -------------------- ---------------------- -----------
  Sex (female)                   3/5                  4/5                    
  Age (years)                    55.2 ± 13.4          60.2 ± 3.66            0.421
  BMI (kg/m^2^)                  22.8 ± 4.6           24.5 ± 5.5             0.516
  Underlying disease                                                         
  AML                            5                    3                      
  ALL                            0                    1                      
  aGvHD onset after SCT (days)   27 ± 19.9            26.6 ± 5.3             0.794
  GvHD (affected organs)                                                     
  Skin                           5                    4                      
  Gastrointestinal tract         5                    5                      
  Liver                          0                    1                      
  Overall grading (Glucksberg)                                               
  2                              2                    1                      
  3                              0                    1                      
  4                              3                    3                      
  Donor type                                                                 
  Relative                       1 (Haploidentical)   2 (1 Haploidentical)   
  Unrelated                      4                    3                      
  Comorbidity index (HCT‐CI)                                                 
  HCT‐CI ≤1                      0                    3                      
  HCT‐CI \>1                     5                    2                      
  HLA match                                                                  
  Full match (12/12)             4                    3                      
  Mismatch                       1                    2                      

Age, body mass index (BMI) and acute graft‐versus‐host disease (aGvHD) onset are shown as the mean. ALL, acute lymphatic leukemia; AML, acute myeloid leukemia; GT, GlucoTab; HCT‐CI, Hematopoietic Cell Transplantation‐Comorbidity Index; HLA, human leukocyte antigen; SCT, stem cell transplantation; SOC, standard of care.
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Primary outcome parameters {#jdi12919-sec-0008}
--------------------------

During in‐hospital glucocorticoid therapy, a total of 364 (GT group) and 1,020 (SOC group) PG values were available. The median overall PG was significantly lower in the GT group (151 \[IQR 123--192\] vs 162 \[IQR 138--193\] mg/dL), as well as median fasting PG (131 \[IQR 113--164\] vs 152 \[IQR 134--18\] mg/dL and bedtime PG (159 \[IQR 133--202\] vs 188 \[IQR 160--211\] mg/dL; *P* \< 0.001, respectively). PG values at lunchtime and in the evening showed no statistically significant difference. A total of 67.2% (GT) versus 60.2% (SOC) of all values were in the recommended target range (70--180 mg/dL; *P* \< 0.001). Hypoglycemia (PG \<70 mg/dL) appeared rarely in both groups with no statistical difference (*P* = 0.120). None of the hypoglycemic events was symptomatically noticed, required third party help or resulted in an adverse clinical outcome. Detailed information on primary outcome parameters is shown in Table [2](#jdi12919-tbl-0002){ref-type="table"}.

###### 

Median glucose during different time‐points, and percentage and amount of values during different glycemic ranges

  Group                                         GT (*n* = 5)   SOC (*n* = 5)   *P*‐value                           
  --------------------------------------------- -------------- --------------- ----------- ----- ---------- ------ ---------
  Median glucose during different time‐points                                                                      
  Median PG morning                             131            113--164        94          152   134--182   286    \<0.001
  Median PG lunch                               148            120--185        92          157   134--182   279    0.421
  Median PG evening                             179            178--223        96          191   157--230   265    0.201
  Median PG bedtime                             159            132--202        82          188   160--211   190    \<0.001
  Median PG total                               151            123--192        364         162   138--193   1020   \<0.001

                                                                     \%     *n*   \%     *n*    *P*‐value
  ------------------------------------------------------------------ ------ ----- ------ ------ -----------
  Percentage and amount of values during different glycemic ranges                              
  Hypoglycemia (\<70 mg/dL)                                          0.8    3     0.2    2      0.120
  Target PG (70--180 mg/dL)                                          67.2   248   60.2   614    0.017
  Hyperglycemia (\>180 mg/dL)                                        32.0   113   39.6   404    0.010
  Total                                                              100    364   100    1020   

GT, GlucoTab; IQR, interquartile range; PG, plasma glucose; SOC, standard of care.
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Secondary outcome parameters {#jdi12919-sec-0009}
----------------------------

The mean total daily insulin dose was significantly higher in the GT (38 ± 29 IU) versus SOC group (11 ± 12 IU), and the mean prednisolone dose was higher in the SOC group (*P* \< 0.001). Table [3](#jdi12919-tbl-0003){ref-type="table"} shows further secondary outcome parameters.

###### 

Secondary outcome parameters

  Group                                   GT (*n* = 5)   SD/IQR    SOC (*n* = 5)   SD/IQR    *P*‐value
  --------------------------------------- -------------- --------- --------------- --------- -----------
  Mean total daily insulin dose (IU)      38             ±29       11              ±12       \<0.001
  Mean prednisolone dose (mg)             85             ±53       98              ±59       \<0.001
  Mean initial prednisolone dose (mg)     113            ±59       140             ±53       0.458
  Median time of survival (days)          105            39--161   136             86--165   0.458
  Median time of hospitalization (days)   41             22--89    101             55--147   0.095
  Median percentage of hospitalization    80             34--95    86              62--97    0.690
  Cause of death (*n*)                    4                        4                         
  Infection (*n*)                         2                        2                         
  Relapse (*n*)                           1                        1                         
  aGvHD (*n*)                             1                        1                         

Normally distributed parameters are given as the mean (standard deviation \[SD\]), non‐normally distributed parameters are presented as the median (interquartile range \[IQR\]). aGvHD, acute graft‐versus‐host disease; GT, GlucoTab; IQR, interquartile range; SD, standard deviation; SOC, standard of care.
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Discussion {#jdi12919-sec-0010}
==========

Patients with aGvHD require high doses of steroids as first‐line immunosuppressant therapy and consecutively frequently develop SIHG[1](#jdi12919-bib-0001){ref-type="ref"}. Recent data showed that patients with aGvHD who develop SIHG face a substantially increased risk for non‐relapse mortality, and this risk correlates with the extent of hyperglycemia[4](#jdi12919-bib-0004){ref-type="ref"}, [6](#jdi12919-bib-0006){ref-type="ref"}.

Although glucose seems to be a prognostic marker, it remains unclear whether lowering hyperglycemia influences survival of these patients, which would need to be tested in an adequately powered outcome trial.

As a first step towards such a trial, we investigated the feasibility of carrying out a randomized controlled trial using a standardized DSS for basal--bolus insulin therapy in hospitalized patients with SIHG, which could serve as a tool for standardized, intensive glucose management in a future multicenter trial.

The present trial showed that median glucose levels were significantly lower in SIHG patients treated with a standardized DSS compared with usual care, without increasing the number of hypoglycemic events. In particular, median morning and bedtime glucose readings were lower in the DSS group, suggesting that the morning short‐acting insulin dose will need to be increased further in the DSS algorithm optimized for steroid‐induced hyperglycemia.

It is well known that patients who use short‐acting or intermediate steroids are exposed to the development of a transient rise of hyperglycemia that persists for some hours. For this reason, future versions of the algorithm will have to be aware of the time‐point of steroid application, and also the type of steroid and its hyperglycemic potency must be taken into account in order to further improve the algorithm. These adjustments are indispensable before the system can be used in a trial investigating the effect of tight glycemic control on patient survival in aGvHD.

Apart from the hereby shown ability of GlucoTab to improve glycemia in patients with SIHG, we have to underline that we tested the device in a hospital unit that employs non‐diabetologists. This emphasizes the potential benefit of GlucoTab to facilitate and standardize glycemic management for non‐specified staff.

To our knowledge, this was the first trial testing a DSS for insulin therapy in patients with SIHG. The present results suggest that GlucoTab might be a suitable tool for the treatment of SIHG in patients suffering from aGvHD and other SIHG patients. Whether or not DSS‐induced improved glycemia translates into a beneficial outcome in patients with aGvHD needs to be investigated in a larger outcome trial.
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